Monocyte chemoattractant protein‐1 and recurrent cardiovascular events in patients with stable coronary heart disease

Abstract

SummaryBackground: Monocyte chemoattractant protein-1 (MCP-1) participates in the recruitment of mononuclear cells to the vessel wall.Hypothesis: The aim of the study was to evaluate the potential association between serum concentration of MCP-1 and risk of future cardiovascular events in patients with chronic coronary heart disease.Methods: A nested case control design was used. Baseline serum samples were taken from patients with coronary heart disease who were enrolled in a secondary prevention study. The MCP-1 levels were measured in those patients who had recurrent cardiovascular events during follow-up (n = 233) and compared with levels in age-and gender-matched controls.Results: There were no differences in serum MCP-1 levels between cases and controls. The relative odds of a recurrent cardiovascular event for each 1 standard deviation difference in MCP-1 serum concentration (160 pg/ml) was 1.19 (95% confidence interval, 0.95-1.45). No increase in the relative odds for recurrent cardiovascular events was observed per increasing tertiles of MCP-1 concentrations.

Reliability of tumor markers, chemokines, and metastasis-related molecules in serum

“…Our results are consistent with previous studies of CA 15-3 [15], MCP-1 [16], and RANTES [17]. To our knowledge, our group is the first to evaluate the temporal reliability of the majority of these biomarkers in healthy individuals, as, other than CA 15-3, CA 125, MCP-1, and RANTES, few markers have been explored in previous research of temporal reliability.…”

Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia

“…The biological role of MCP-1 in EI is also reflected by its altered plasma levels in AH patients, particularly those with a clinical sequela of acute coronary syndromes [9], as well as by its deregulated production in other cardiovascular diseases [10]. However, both cellular and molecular mechanisms that drive its enhanced solubilization in AH have received little attention.…”

Non‐traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?

“…The study consisted of 233 patients that had recurrent MI, sudden cardiac death or ischemic stroke during follow-up and control group of 233 patients, free of CV event that were matched to cases by age, gender, and allocation to bezafibrate or placebo. Baseline MCP-1 concentration was not found predict risk of early or late CV events during the long-term follow-up period (13).…”